Lack of complications in patients with eosinophilic gastrointestinal diseases during SARS-CoV-2 outbreak

Abstract

Eosinophilic gastrointestinal diseases (EGIDs) are chronic immune/antigen-mediated disorders characterized by eosinophilic inflammation. They can affect the esophagus (eosinophilic esophagitis [EoE]), the stomach, and the small bowel (eosinophilic gastroenteritis [EGE]) and the colon (eosinophilic colitis [EC]). Medical therapies consist primarily of proton pump inhibitors (PPIs) or orally administered topical corticosteroids for EoE. Systemic corticosteroids or biologics are used in case of refractory EoE and in case of EGE and EC, despite the well-known adverse events associated with their long-term administration.